June 30, 2022
https://doi.org/10.23999/j.dtomp.2022.6.1
J Diagn Treat Oral Maxillofac Pathol 2022;6:77–81.
Under a Creative Commons license
Tymofieiev OO, Ripa VM, Havlytiuk DS, Sokoliuk MA, Kolisnichenko LA. Prevention of post-implantation complications. J Diagn Treat Oral Maxillofac Pathol 2022;6(6):77–81.
Purpose: Currently, dental prosthetics on endosseous implants is used in most dental clinics of Ukraine. The incidence of inflammatory complications after the surgical stage of dental implantation, according to different authors, ranges from 0.4 to 5 percent. Therefore, many doctors during the surgical stage of dental implantation are looking for medications that simultaneously have both anti-inflammatory and analgesic effects. The purpose of this study is to determine the effectiveness of the treatment of early post-implantation complications when using the drug “Trachisan®” and compare its effectiveness with the traditionally used therapy.
Materials and Methods: According to our observation, there were 24 patients aged from 20 to 56 years (1st observation group or main group). We prescribed Trachisan to these patients in the post-implantation period for 4 days. The control group consisted of 30 patients (2nd observation group or the control group), who were treated with traditional methods in the post-implantation period (Analgin tablets [metamizole sodium] and conventional antiseptic rinses).
Results: Inflammatory complications in the 1st (main) group were not detected, and in the 2nd (control) group, inflammatory complications were diagnosed in 7 patients (23.3 percent), namely: mucositis – in 4 patients (13.3 percent) and peri-implantitis – in 3 patients (10 percent).
Conclusions: Thus, the drug “Trachisan” should be recommended for widespread use in maxillofacial surgery after the surgical stage of dental implantation to prevent post-implantation inflammatory complications.